Biogen Inc. · NASDAQ
Zacks Investment Research
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about BIIB?
Zacks Investment Research
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseBiogen is expected to report Q3 2026 earnings on October 28 with a consensus EPS estimate of $2.04 per share (down 57.6% YoY) and revenues of $2.59 billion (up 2% YoY). With a positive Earnings ESP of +1.81% and Zacks Rank #3 (Hold), the company appears positioned to beat consensus estimates. Biogen has beaten EPS estimates in all four of the last quarters.
Zacks Investment Research
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Biogen Inc. (BIIB) has demonstrated a consistent pattern of beating earnings estimates, with an average surprise of 19.72% over the last two quarters. The company reported $3.6 per share versus an expected $3.04, and $3.57 versus expected $2.95 in the previous quarter. With a positive Earnings ESP of +2.19% and a Zacks Rank #3 (Hold), analysts suggest another earnings beat is likely when the company reports on October 28, 2026.
Headlines link to the publisher. Not investment advice.
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Sign in to post on $BIIB
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
